PER-012-09已完成未知
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2009年4月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 78（—）
- 性别
- All
入选标准
- •Man, non-fertile women or women with the potential to become pregnant who use a medically approved method of birth control.
- •Age in the range of 18 - 78 years inclusive in Visit 1.
- •Patients with DMT2 treated with metformin for at least 3 months and with a stable dose of at least 1,500 mg daily for a minimum of 4 weeks before Visit 1.
- •Agreement to maintain the same dose of metformin throughout the study.
- •HbA1c> 7.0 and <9.5% in Visit 1.
- •Body Mass Index (IMG) in the range of 22 - 45 kg / m2 in Visit 1.
排除标准
- •Pregnant or nursing women (breastfeeding).
- •GPA> 270 mg / dL (> 15.0 mmol / L).
- •Any of the following significant laboratory abnormalities: Clinically significant TSH outside the normal range at Visit 1. Clinically significant renal dysfunction indicated by serum creatinine levels> 1.5 mg / dL (132 pmol / L) for men and> 1.4 mg / dL (123 pmol / L) for women at Visit 1 or a history of abnormal creatinine clearance. High fasting triglycerides> 500 mg / dL at Visit 1 confirmed with repeated measurement within 3 working days. Alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST)> 2 X upper limit of normal (ULN) in Visit 1, confirmed by a repeated measure within 3 working days. Total bilirubin> 2 x ULN and / or direct bilirubin> of ULN in Visit 1 confirmed by a repeated measurement within 3 working days. Hepatitis B surface antigen (HBsAg) positive. Hepatitis C antibody test (anti-HCV positive). Clinically significant laboratory abnormalities in the opinion of the researcher.
- •Congestive heart failure requiring pharmacological treatment.
- •A history of: Type 1 diabetes, diabetes that is the result of pancreatic injury or secondary forms of diabetes, eg, Cushing´s syndrome and acromegaly. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar condition (coma) in the last 6 months. Liver disease, such as cirrhosis or active chronic hepatitis B or C.
- •Any of the following in the last 6 months: Myocardial infarction (MI) (if the ECG of Visit 1 reveals patterns consistent with an IM and the date of the event cannot be determined, then the patient can enter the study at discretion of the researcher and the sponsor). Unstable angina. Coronary artery bypass surgery or percutaneous coronary intervention. Stroke
- •Any of the following ECG abnormalities: Torsades de pointes, clinically relevant and sustained ventricular tachycardia or ventricular fibrillation. Second degree AV block (Mobitz 1 and 2). Third degree AV block. Prolonged QTc (> 500 ms).
- •Treatment with any oral antidiabetic therapy other than metformin within 3 months prior to Visit 1.
- •Chronic insulin treatment (> 4 weeks of treatment in the absence of an intercurrent disease) in the last 6 months.
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesEUCTR2008-004722-16-GBovartis Pharma Services AG2,500
已完成
2 期
A study to evaluate the effictiveness and safety of Vildagliptin in Subjects With Type 2 Diabetes.CTRI/2009/091/000134ovartis Healthcare Private Limited452
进行中（未招募）
1 期
International clinical study to compare cadazolid to vancomycin to treatCDADEUCTR2013-002528-17-DEActelion Pharmaceuticals Ltd630
进行中（未招募）
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesType II DiabetesEUCTR2008-004722-16-ATovartis Pharma Services AG2,500
进行中（未招募）
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesType II DiabetesEUCTR2008-004722-16-BEovartis Pharma Services AG2,500